Advertisements


Piper continues to expect Alnylam"s Givosiran to be approved in 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Lumasiran could give Alnylam 3 RNAi drugs approved by 2021, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Piper Jaffray confident in Alnylam Givosiran approval

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2018

Data On Givosiran And Lumasiran Should Help The Alnylam Story

Data On Givosiran And Lumasiran Should Help The Alnylam Story.....»»

Category: topSource: seekingalphaApr 16th, 2019

Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic .....»»

Category: dealsSource: nytApr 15th, 2019

Positive givosiran data largely priced into Alnylam, says Nomura Instinet

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Alnylam data affirm efficacy of givosiran, ease safety concerns, says Stifel

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Alnylam"s Givosiran study met primary efficacy endpoint in AHP treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 12th, 2019

Alnylam alliance with Regeneron a "clear positive," says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2019

Most of Wall Street thinks Trump will be re-elected in 2020

A new poll of Wall Street insiders shows that a vast majority expect President Donald Trump to win re-election in 2020......»»

Category: topSource: moneycentralApr 5th, 2019

Most of Wall Street thinks Trump will be reelected in 2020

A new poll of Wall Street insiders shows that a vast majority expect President Donald Trump to win reelection in 2020......»»

Category: topSource: moneycentralApr 5th, 2019

Here"s who most investors expect to win in 2020

And which Democrats they least want to see in the White House......»»

Category: topSource: foxnewsApr 5th, 2019

Global Trade Growth Slashed Again As Trade Tensions Persist

The World Trade Organization published a new report that shows world trade is projected to "face strong headwinds" into 2020. WTO economists expect merchandise trade volume growth to drop to 2.6% in 2019, down.....»»

Category: blogSource: zerohedgeApr 4th, 2019

Piper continues to believe Apyx Medical will receive 510k clearance

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

‘Law & Order: SVU’ to Become the Longest-Running Drama in Prime-Time History

When the show returns for its 2019-2020 season, it will become the longest-running prime-time drama ever. Don’t expect Olivia Benson to hand in her badge any time soon. NBC’s Law & Order: Special.....»»

Category: europeSource: fortuneMar 29th, 2019

Nvidia Gets Boost From Bullish Piper Jaffray Initiation

Shares of Nvidia Corporation (NASDAQ: NVDA) are trading at around 33.3 times Piper Jaffray's 2020 estimated non-GAAP EPS, which undervalues the company given multiple catalysts ahead. Latest Ratings for NVDA DateFirmActionF.....»»

Category: blogSource: benzingaMar 26th, 2019

Piper continues to recommend Biogen shares after deeper dive on BIIB067

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 26th, 2019

Raymond James Expects Johnson & Johnson"s Growth To Accelerate Into 2020

Johnson & Johnson’s (NYSE: JNJ) bottom line continues to be come under pressure from forex and generic competition, and the company faces sentiment-related headwinds, according to Raymond James. Latest Ratings for JNJ .....»»

Category: blogSource: benzingaMar 25th, 2019

Will Washington State"s Plan To Ban Trump From The 2020 Ballot Backfire?

Authored by Jeff Charles via LibertyNation.com, Dems getting creative in amending federal election laws, but will it backfire? Well, you’ve got to hand it to them. The progressive left continues to find new and cr.....»»

Category: blogSource: zerohedgeMar 20th, 2019

Takeaways from the ballpark development agreement discussion

The Wichita City Council approved 7-0 the third leg of the agreement between the city and Wichita Baseball 2020......»»

Category: topSource: bizjournalsMar 20th, 2019

The Ratings Game: Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout

Shares of Sage Therapeutics Inc. rose 3% Wednesday morning after the company’s announcement Tuesday evening that the Food and Drug Administration had approved its drug for the treatment of postpartum depression......»»

Category: topSource: marketwatchMar 20th, 2019